Katharine Knobil
2019
In 2019, Katharine Knobil earned a total compensation of $1.3M as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences, a 70% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $170,252 |
|---|---|
| Option Awards | $583,729 |
| Salary | $450,000 |
| Other | $47,783 |
| Total | $1,251,764 |
Knobil received $583.7K in option awards, accounting for 47% of the total pay in 2019.
Knobil also received $170.3K in non-equity incentive plan, $450K in salary and $47.8K in other compensation.
Rankings
In 2019, Katharine Knobil's compensation ranked 8,213th out of 13,971 executives tracked by ExecPay. In other words, Knobil earned more than 41.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,213 out of 13,971 | 41st |
Division Manufacturing | 3,241 out of 5,701 | 43rd |
Major group Chemicals And Allied Products | 1,228 out of 2,200 | 44th |
Industry group Drugs | 1,043 out of 1,886 | 45th |
Industry Biological Products, Except Diagnostic Substances | 235 out of 389 | 40th |
Source: SEC filing on May 8, 2020.
Knobil's colleagues
We found four more compensation records of executives who worked with Katharine Knobil at Kaleido Biosciences in 2019.